CA-MCAFEE
24.7.2024 06:02:35 CEST | Business Wire | Press release
Today, McAfee Corp., a global leader in online protection, announced the extension of its ten-year partnership with Samsung, enabling enhanced protection for online threats to consumers’ privacy, identity and personal information.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723762355/en/
McAfee and Samsung Extend Partnership for 10th Year, Expand AI-Powered Online Protection for Samsung Customers Around the Globe via Galaxy Store (Photo: Business Wire)
Now, Samsung mobile devices, including the Galaxy S24 Ultra, Galaxy S24, Galaxy S24+, Galaxy Tab S9 series, Galaxy Z Flip6, and Galaxy Z Fold6, come with the Galaxy Store pre-installed. This is where users can download and use the McAfee Security app* that includes McAfee Scam Protection™, the company's patented AI technology that automatically identifies and alerts you if it detects a dangerous URL in your text messages. It also proactively blocks risky sites if you accidentally click on a scam link in a text, email, social media post, and more.
In addition to being available on consumer Galaxy phones and tablets, McAfee Security is now available for purchase for existing customers in 98 markets via the Galaxy Store. Consumers can easily buy and install the app on their Samsung mobile device, ensuring uninterrupted online protection. This is particularly important at a time when, with the rise of AI, cybercriminals are creating more convincing, personalized scams at scale, making it harder than ever for consumers to know what content to trust: 50% of mobile phone users say AI has made it harder for them to spot online scams and 39% of respondents admit to having clicked on text scam messages, such as a suspicious text from an unknown number or a fake package delivery text.**
These capabilities also help address key consumer concerns: according to McAfee’s recent Mobile Threat Survey, 90% of people globally are concerned about protecting their online privacy and identity when using their mobile phone. To further combat this concern in the age of AI, the latest Galaxy devices also come equipped with Advanced Intelligence settings***, giving users full control over how much they allow their data to enhance AI experiences by disabling online data processing.
"Our continued partnership with Samsung helps us do what matters most: protect more people so they can live their lives online with confidence," said Pedro Gutierrez, Senior Vice President at McAfee. "With the introduction of Samsung's new mobile AI experience and McAfee's continued focus on using AI to fight against AI scams, we’re thrilled to continue our partnership."
Samsung Galaxy devices, including the Galaxy S24 series, Galaxy Tab S9 series, Galaxy Z Flip6, and Galaxy Z Fold6, now offer McAfee Security with McAfee Scam Protection™ available at a special price through the pre-installed Galaxy Store app. This wide range of available devices with McAfee online protection solutions helps give users comprehensive protection against evolving online threats.
About McAfee
McAfee Corp. is a global leader in online protection for consumers. Focused on protecting people, not just devices, McAfee’s consumer solutions adapt to users’ needs in an always online world, empowering them to live securely through integrated, intuitive solutions that protect their families, communities, and businesses with the right security at the right moment. For more information, please visit https://www.mcafee.com.
_____________________________
* The McAfee Security app available in the Samsung Galaxy Store is McAfee Total Protection™ that includes McAfee Scam Protection, McAfee's patented and powerful Artificial Intelligence (AI) technology that protects against the surge in AI-generated phishing scams.
** McAfee Mobile Threat Survey February 2024 conducted by Market Research Company MSI-ACI with 4,032 adults from 7 countries including the United States, United Kingdom, France, Germany, Australia, India, and Japan.
*** Samsung Account login required. Advanced Intelligence settings preventing server access will limit the functionality of some AI features. Regardless of server access, Samsung does not save user input or output data. Different terms may apply for AI features provided by third parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723762355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom